MiRNA-576 Alleviates the Malignant Progression of Atherosclerosis Through Downregulating KLF5

Overview

Journal Dis Markers

Publisher Wiley

Specialty Biochemistry

Date 2021 Dec 20

PMID 34925646

Citations 1

Authors

Jing Wang

Lihui Zhang

Ting Wang

Caige Li

Lijing Jiao

Zhansheng Zhao

Yongjun Li

Affiliations

Soon will be listed here.

Abstract

Objective: To elucidate the role of microRNA-576 (miRNA-576) in alleviating the deterioration of atherosclerosis (AS) through downregulating krüpple-like factor 5 (KLF5).

Materials And Methods: The AS model in mice was first constructed. Body weight, inflammation degrees, blood lipid, and relative levels of KLF5, miRNA-576, caspase-3, and bcl-2 in AS mice and control mice were compared. Dual-luciferase reporter gene assay was performed to evaluate the binding between miRNA-576 and KLF5. RAW264.7 cells were treated with 200 mg/L ox-LDL for establishing high-fat model. Regulatory effects of miRNA-576/KLF5 on relative levels of -catenin and inflammatory factors in RAW264.7 cells were explored.

Results: Body weight was heavier in AS mice than in controls. Protein levels of KLF5 and caspase-3 were upregulated, while bcl-2 was downregulated in AS mice. In particular, protein level of KLF5 was highly expressed in aortic tissues of AS mice. TC and LDL increased, and HDL decreased in AS mice compared with controls. Inflammatory factor levels were markedly elevated in AS mice. KLF5 was verified to be the target gene binding miRNA-576. Overexpression of miRNA-576 downregulated KLF5, inflammatory factors, and -catenin in ox-LDL-treated RAW264.7 cells. Regulatory effect of miRNA-576 on the release of inflammatory factors in RAW264.7 cells could be partially abolished by KLF5.

Conclusions: miRNA-576 alleviates malignant progression of AS downregulating KLF5.

Citing Articles

Participation of Krüppel-like Factors in Atherogenesis.

Kotlyarov S, Kotlyarova A Metabolites. 2023; 13(3).

PMID: 36984888 PMC: 10052737. DOI: 10.3390/metabo13030448.

References

Ouimet M, Ediriweera H, Afonso M, Ramkhelawon B, Singaravelu R, Liao X . microRNA-33 Regulates Macrophage Autophagy in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2017; 37(6):1058-1067. PMC: 5494696. DOI: 10.1161/ATVBAHA.116.308916. View

Yue X, Cao D, Lan F, Pan Q, Xia T, Yu H . MiR-301a is activated by the Wnt/β-catenin pathway and promotes glioma cell invasion by suppressing SEPT7. Neuro Oncol. 2016; 18(9):1288-96. PMC: 4998999. DOI: 10.1093/neuonc/now044. View

Shimizu Y, Kuge Y . Recent Advances in the Development of PET/SPECT Probes for Atherosclerosis Imaging. Nucl Med Mol Imaging. 2016; 50(4):284-291. PMC: 5135693. DOI: 10.1007/s13139-016-0418-9. View

Wu C, Luan H, Zhang X, Wang S, Zhang X, Sun X . Chlorogenic acid protects against atherosclerosis in ApoE-/- mice and promotes cholesterol efflux from RAW264.7 macrophages. PLoS One. 2014; 9(9):e95452. PMC: 4154672. DOI: 10.1371/journal.pone.0095452. View

Bell K, Shroyer N . Krüpple-like factor 5 is required for proper maintenance of adult intestinal crypt cellular proliferation. Dig Dis Sci. 2014; 60(1):86-100. PMC: 4286443. DOI: 10.1007/s10620-014-3307-z. View

Ulrich V, Rotllan N, Araldi E, Luciano A, Skroblin P, Abonnenc M . Chronic miR-29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Mol Med. 2016; 8(6):643-53. PMC: 4888854. DOI: 10.15252/emmm.201506031. View

Liao X, Haldar S, Lu Y, Jeyaraj D, Paruchuri K, Nahori M . Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol. 2010; 49(2):334-8. PMC: 2885477. DOI: 10.1016/j.yjmcc.2010.04.008. View

Zhang X, Shao S, Geng H, Yu Y, Wang C, Liu Z . Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study. J Clin Endocrinol Metab. 2014; 99(5):E766-74. DOI: 10.1210/jc.2013-1629. View

Hall I, Climent M, Viviani Anselmi C, Papa L, Tragante V, Lambroia L . rs41291957 controls miR-143 and miR-145 expression and impacts coronary artery disease risk. EMBO Mol Med. 2021; 13(10):e14060. PMC: 8495461. DOI: 10.15252/emmm.202114060. View

10.

Xiong J, Ma F, Ding N, Xu L, Ma S, Yang A . miR-195-3p alleviates homocysteine-mediated atherosclerosis by targeting IL-31 through its epigenetics modifications. Aging Cell. 2021; 20(10):e13485. PMC: 8520716. DOI: 10.1111/acel.13485. View

11.

Tang T, Du X, Zhang X, Niu W, Li C, Tan J . Computational identification and analysis of early diagnostic biomarkers for kidney cancer. J Hum Genet. 2019; 64(10):1015-1022. DOI: 10.1038/s10038-019-0640-2. View

12.

Wang W, Zhang Y, Wang L, Li J, Li Y, Yang X . mircroRNA-152 prevents the malignant progression of atherosclerosis via down-regulation of KLF5. Biomed Pharmacother. 2018; 109:2409-2414. DOI: 10.1016/j.biopha.2018.08.014. View

13.

Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W . Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics. 2016; 6(4):533-44. PMC: 4775863. DOI: 10.7150/thno.14315. View

14.

Ulrich C, Trojanowicz B, Fiedler R, Kohler F, Wolf A, Seibert E . Differential Expression of Lipoprotein-Associated Phospholipase A2 in Monocyte Subsets: Impact of Uremia and Atherosclerosis. Nephron. 2016; 135(3):231-241. DOI: 10.1159/000454778. View

15.

Zhou Y, Little P, Ta H, Xu S, Kamato D . Lysophosphatidic acid and its receptors: pharmacology and therapeutic potential in atherosclerosis and vascular disease. Pharmacol Ther. 2019; 204:107404. DOI: 10.1016/j.pharmthera.2019.107404. View

16.

Drosatos K, Pollak N, Pol C, Ntziachristos P, Willecke F, Valenti M . Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function. Circ Res. 2015; 118(2):241-53. PMC: 4886555. DOI: 10.1161/CIRCRESAHA.115.306383. View

17.

Blaser M, Aikawa E . Differential miRNA Loading Underpins Dual Harmful and Protective Roles for Extracellular Vesicles in Atherogenesis. Circ Res. 2019; 124(4):467-469. PMC: 6383776. DOI: 10.1161/CIRCRESAHA.119.314596. View

18.

Liu Y, Chen J, Dai M . Paeonol protects rat vascular endothelial cells from ox-LDL-induced injury in vitro via downregulating microRNA-21 expression and TNF-α release. Acta Pharmacol Sin. 2014; 35(4):483-8. PMC: 4813724. DOI: 10.1038/aps.2013.190. View

19.

Yan H, Wang S, Li Z, Zhao W, Wang Z, Sun Z . Upregulation of miRNA-155 expression by OxLDL in dendritic cells involves JAK1/2 kinase and transcription factors YY1 and MYB. Int J Mol Med. 2016; 37(5):1371-8. DOI: 10.3892/ijmm.2016.2526. View

20.

Neth P, Nazari-Jahantigh M, Schober A, Weber C . MicroRNAs in flow-dependent vascular remodelling. Cardiovasc Res. 2013; 99(2):294-303. DOI: 10.1093/cvr/cvt096. View